These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31052478)

  • 21. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
    Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
    Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD
    Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.
    Estrada S; Lubberink M; Thibblin A; Sprycha M; Buchanan T; Mestdagh N; Kenda B; Mercier J; Provins L; Gillard M; Tytgat D; Antoni G
    Nucl Med Biol; 2016 Jun; 43(6):325-32. PubMed ID: 27260773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-in-Human Evaluation of
    Naganawa M; Li S; Nabulsi N; Henry S; Zheng MQ; Pracitto R; Cai Z; Gao H; Kapinos M; Labaree D; Matuskey D; Huang Y; Carson RE
    J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential of [
    Puuvuori E; Rokka J; Carlsson PO; Li Z; Eriksson J; Eriksson O
    Sci Rep; 2021 Dec; 11(1):24466. PubMed ID: 34963683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats.
    Onwordi EC; Halff EF; Whitehurst T; Mansur A; Cotel MC; Wells L; Creeney H; Bonsall D; Rogdaki M; Shatalina E; Reis Marques T; Rabiner EA; Gunn RN; Natesan S; Vernon AC; Howes OD
    Nat Commun; 2020 Jan; 11(1):246. PubMed ID: 31937764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
    Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
    J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [
    Marstrand-Joergensen MR; Laurell GL; Herrmann S; Nasser A; Johansen A; Lund A; Andersen TL; Knudsen GM; Pinborg LH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3292-3304. PubMed ID: 38758370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [
    Xiao L; Xiang S; Chen C; Zhu H; Zhou M; Tang Y; Feng L; Hu S
    Psychiatry Clin Neurosci; 2024 Aug; 78(8):456-467. PubMed ID: 38804583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.
    Dong M; Liu H; Tepp WH; Johnson EA; Janz R; Chapman ER
    Mol Biol Cell; 2008 Dec; 19(12):5226-37. PubMed ID: 18815274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.
    Mercier J; Archen L; Bollu V; Carré S; Evrard Y; Jnoff E; Kenda B; Lallemand B; Michel P; Montel F; Moureau F; Price N; Quesnel Y; Sauvage X; Valade A; Provins L
    ChemMedChem; 2014 Apr; 9(4):693-8. PubMed ID: 24446373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SV2A and SV2C contain a unique synaptotagmin-binding site.
    Schivell AE; Mochida S; Kensel-Hammes P; Custer KL; Bajjalieh SM
    Mol Cell Neurosci; 2005 May; 29(1):56-64. PubMed ID: 15866046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synaptic Terminal Density Early in the Course of Schizophrenia: An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A.
    Onwordi EC; Whitehurst T; Shatalina E; Mansur A; Arumuham A; Osugo M; Marques TR; Jauhar S; Gupta S; Mehrotra R; Rabiner EA; Gunn RN; Natesan S; Howes OD
    Biol Psychiatry; 2024 Apr; 95(7):639-646. PubMed ID: 37330164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential expression of synaptic vesicle protein 2 (SV2) isoforms.
    Bajjalieh SM; Frantz GD; Weimann JM; McConnell SK; Scheller RH
    J Neurosci; 1994 Sep; 14(9):5223-35. PubMed ID: 8083732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.